projects that show promise for commercial development have been selected to
share $500,000 from the Innovation Fund at Cincinnati Children’s and $100,000
from the Greater Cincinnati Foundation.
The fund – now in
its second year – provides early-stage bridge funding to further develop
discoveries into medically and commercially viable products ready for outside
Fund allows the medical center to select promising projects developed by its
researchers and accelerate their bench-to-bedside transition and entry to the
patient care market,” says Niki Robinson, PhD, assistant vice president of the
Center for Technology Commercialization (CTC). “This funding provides crucial financial
support at a critical time to projects that otherwise might not continue their
Denson, MD, Gastroenterology:
Development of a diagnostic technology that can distinguish between Crohn’s
disease and ulcerative colitis.
(Chuck) Dumoulin, PhD, Radiology: Continued development of a novel neonatal MRI scanner for
premature babies who are frequently too fragile to transport beyond the NICU.
Hardie, MD, Pulmonary Medicine: Confirming the effectiveness of a prospective oral therapy
that would target a specific molecule (P70S6K) to reverse pulmonary
Malik, MD, Experimental Hematology and Cancer Biology: Continued study of an improved
y-globin gene developed for a prospective Phase I/II clinical trial of gene
therapy for sickle cell disease.
Sadhasivam, MD, MPH, Anesthesia : Development of a rapid point-of-care genetic test and
decision support tool that allows physicians to precisely tailor the use of
opioids for pain management.
Wong, MD, Division of Critical Care Medicine – Further testing of a novel diagnostic biomarker (IL-27)
for rapid and early identification of sepsis in patients.